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Objectives. This study sought to investigate the effects of nitric 
oxide inhibition in a murine model of coxsackievims II3 myocar- 
ditis. 
Buckground. Little is known about the contribution of nitric 
oxide to the pathophysiology of myocarditis. 
Methods. Antiviral activity was testd in vitro using nitric oxide 
inhibition by treatment with activated macrophages of N”-nitro- 
L-arginine methyl ester. In the in vivo experiments, N’;-nitro+ 
arginine methyl ester and N”-nitro-u-arginine methyl ester (both 
at 100 &ml) were administered to WI/He mice early (days 0 to 
14) and late (days 14 to 35) after infection with CoXSa~kkVirU~ B3. 
RrsutVs. In the in vitro experiments with isterferon-gamma- 
and lipopolysaccharide-induced activated q urine macrophages, 
treatment with the nitric oxide syntbase inhibitor NC’-nitr+L- 
arginine methyl ester, but not its inactive enantiomer NC’-nitro-u- 
arginine methyl ester, restored coxsatkievi~s Ii3 titers. In the in 
Coxsackievirus B3 is an enterovirus that can cause acute 
myocarditis in humans and mice (l-3). T cells and cytokines, 
especially interleukin-2 and interferons, are involved in the 
pathogenesis of acute coxsackievirus B3 myocarditis (4-8). 
Nitric oxide is a gaseous free-radical molecule that has been 
shown (9-13) to be a mediator of vital physiologic functions. 
Recent evidence has suggested (14) that nonspecific immunity 
is associated with the induction of nitric oxide synthase. Many 
cell types are capable of producing nitric oxide through the 
enzymatic conversion of L-arginine to L-citrulline by nitric 
oxide synthase (9-13). In inflamed tissue, inducible nitric oxide 
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vivo experiments in thr early treatment group, myocardial virus 
titers were higher in N”-nitro+arginine methyl ester-W&d 
than infected untreakxl animals, and both inflammatory cell 
infiltration and q ecmsis were more severe. In the late treatment 
group, more severe necmsis and more dense myocardial and 
perivascular fibrosis were observed in NC-nitro+arginine metlryl 
ester-treated than in infected untreated animals. N’;-Nitro-u- 
arginine methyl ester administration was inektive. 
Conclusions. Nitric oxide inhibition increases myocardial virus 
titers, resulting in the aggravation ~t’cnrdiac pathology in the 
early stage of coxsackievirus II3 myocarditis. In the late stage, it 
induces more severr cardiomyopathic lesions. Nitric oxide plays a 
defensive mle in the pathogenesis of coxsackievirus B3 myocar- 
ditis. 
(J Am cdl GInlid 19%;28:1610-5) 
synthase is expressed by macrophage production in large 
quantities of nitric oxide and low pulsatile production of nitric 
oxide through constituent nitric oxide synthase from the endo- 
thelium. In addition, a potential dual role of nitric oxide has 
been reported (14). 
In the present study, we investigated the effects of inhibition 
of nitric oxide synthase on coxsackievirus B3 replication with 
an in vitro viral sensitivity assay. This investigation was fol- 
lowed by an in vivo experiment in mice with coxsackievirus B3 
myocarditis treated with nitric oxide synthase inhibitors. 
Methods 
We performed not only in vitro experiments, in which 
ml;rine macrophages were treated with the inhibition of nitric 
oxide synthase, but also in vivo experiments, in which coxsack- 
ievirus BIinfected mice were treated with the nitric ,oxide 
synthase inhibitor p-&tro-L-arginine methyl ester. and its 
inactive analogue p-nitro-oarginine-methyl ester, and sur- 
vival rates’and histopathologic findings yeie examined. 
InWroSh4dy 
The in vitro viral sensitivity protocol was performed acc&d- 
ing to recently published methods (15,16) with minor modifi- 
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cations. Afier confirming that macrophages, on stimulation 
with interfero’n,‘(IFN)-gamma and lipoljolysaccharide, de- 
crease cpxsackievirus 93 tiiers, we determined whether the 
.,presence of NG-nitro-L-arginine methyl ester reverses this 
effect; resulting in an increase in viral titers. 
Virus and cells. The murine -macrophage-like cell line 
RAW264.7 (17) (TIB71, American Type Culture Collection) 
and VERO African green monkey kidney cells were used. 
RAW264.7 cells are murine macrophages transformed with 
the Abelson leukemia virus that produce nitric oxide when 
stimulated with IFN-gamma or lipopolysaccharide, or both 
(17). 
Coxsackievirus 93 (myocarditic Nancy strain; American 
Type Culture Collection) was used. Virus stock had a titer 
>109 plaque-forming units/O.1 ml. Virus suspensions were 
stored at -80°C until use (4-8). 
Procedures. Commercially available NC’-nitro-L-arginine 
methyl ester and the inactive enantiomer fl-nitro-o-arginine 
methyl ester (Research Biochemicals International) were used. 
RAW264.7 cells were inoculated into six-well plates (3 X 
lO%ell) and incubated at 37°C for 24 h. The cells were 
activated with INF-gamma (50 U/ml) and lipopolysaccharide 
(50 @ml). Two concentrations (270 and 2,700 PmoVliter) of 
NG-nitro-L-arginine methyl ester or .p-nitro-o-arginine 
mct~yl ester Pete tLen added immechately to these cells. Six 
hours later, zeated cells were infected with coxsackievirus 93 
at a multiplicity of infection of 5 plaque-forming units/cell. 
Twenty-four hours later, the infected cells were treated by 
freezing and thawing. The virus titers in the supematants were 
determined by a previously described plaque assay method 
(4-8). 
In I/iv0 study 
Infection protocol. Two-week old male, inbred, certified 
virus-free C$l/He mice (Shizuoka Laboratory Animal Center, 
Shizuoka, Japan) were csec. The animals were inoculated 
intraperitoneally with 0.1 ml of virus suspension containing ld 
plaque-forming units. All animals were cared for in accordance 
with the institutional policies and guidelines of Toyama Med- 
ical and Pharmaceutical University. 
Tmahnent protocot. C,H/He mice were infected with cox- 
sackievirus 93, and No-nitro-L-arginine methyl ester and NG- 
nitro-o-arginine methyl ester were administered orally by 
means of the drinking water (100 &ml), beginning immedi- 
ately after vi? inoculation until day 14 (experiment I: p- 
citro+arginine methyl ester, n = 53; I@-nitro-earginine 
methyl ester, n = 47) and from day 14 until day 35 (experiment 
II: @-nitro-L-arginine methyl estei, n = 16; @-nitreD- 
arginine methyl ester, n = 16). Control infected and untreated 
mice (experiment I, n = 42; experiment II, n = 16) were also 
prepared. The mice consumed p-nitro-L-a@& methyl 
ester or I@j-nitro-o-arginine methyl ester ad liiitum, and daily 
fluid consumption was monitored; there were five animals per 
cage, and all were uniformly treated. Estimated dose (42 m@cg 
body weight per day) was based on Fluid consumption and drug 
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concentration. This oral roule of administra!ion, in the dose 
range studied. has been shown (14) ‘to produce systemic 
inhibition of nitric oxide synthasc. 
In experiment 1. six mice on day 4 and 13 mice on. da;? i in 
each of the three @oupS were killed for ‘evaluation, of early 
cardiac pathologic and virologic analysis. Thus. 34 mike in the 
N”-nitro-L-arginine methyl ester group, 28 mice in No-nitro- 
o-arginine methyl ester grb:!p and 13 mice in the control group 
were used for survival analysi.;. Before starting cxperiaent II. 
an additional five mice from t&ch of the three groups were 
killed to confirm the homogeneity of the groups. Mice were 
obsened daily, and complete autopsy studies were performed 
in those found dead. 
In parallel with experiment I, additional control groups of 
uninfected mice (five treated with N”-nitro+-arginine methyl 
ester, five treated with NG-nitro-o-arginine methyl ester, five 
untreated) were’ also studied for 14 days. 
Vim titers of heart. For infectivity assays, hearts were 
removed aseptically, weighed and homogenized in 2 ml of 
Eagle’s minimum essential medium. Plaque assays of the 
supematants were performed (45). 
PaMogic analysis. The hearts were processed by stan- 
dard methods and stained with hematoxylin-eosin and 
Mallory&an to identify repairing fibrosis and elastic van 
Gieson to evaluate the remodeling of intramyocardial arteries. 
Myocardial sections were graded by two of the authors 
(Y.H., C.K.) who had no knowledge of the respective treat- 
ment groups on a scale of l+ (mild) to 5s (very severe) for 
severity of cellular infiltration, necrosis, calcification, or inter- 
stitial and perivascular fibrosis (7,8). Architectural changes in 
coronary vasculature were also noted. 
Statistics. One-way analysis of variance with multiple sam- 
ple comparisons (Bonferroni) was used to evaluatr differences 
in the virus titers of the hearts and pathologic scor’fs. The 
Kaplan-Meier method was used to determine the differences in 
survival rates (18). Results are reported as mean value 2 SD. 
Results 
Zn Mtfo Study 
I!&etx of NC-nih~-muim methyl ester and NG-nitro- 
Darginiac methyl ester on coxsaekievirus 93 repkation in 
e (Fy 1). In this experiment, nitric oxide synthase 
inhibition was used to determine whether nitric oxide or other 
reactive nitrogen inte:lmtJia~er tiulributrd to the inhibition of 
coxsackievirus 93 replication in macrophages. As shown in 
Figure l,.on stimulation with INF-gamma and Ii-ha- 
ride, macrophages decreased virus titers, and treatment with 
@-nitro-L-arginine methyl ester, but not I@-nit*&arginine 
methyl ester, substantialIy reduced the ability of INF-gamma- 
and lipopolysaccharide-stimulated macrophages to inhibit cox- 
sackievirus B3 replication. Thus, treatment with NG-nitr*L- 
arginine methyl ester restored coxsackievims 93 titers in 
activated macrophages. 
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Figure 1. Viral sensitivity of N”-nitro+-arginine methyl ester (L- 
NAME) and NC-nitro-o-arginine methyl ester (D-NAME). Inhibitors 
of nitric oxide synthase reversed the antiviral effects of interferon- 
_eamma (IFN-y)- and lipopolysaccharide (LPS)-stimulated RAW264.7 
macrophages inoculated with coxsackievirus B3. Confluent monolayers 
of dAWX4.7 mscrophages were activated by INF-gamma (50 U/ml) 
and lipopolysaccharide (50 @ml). Then. two concentrations (770 and 
2.700 ~mol/liter) (if N”-nitro-I.-arginine methyl ester or N”-nitro-o- 
arginine methyl ester were added immediately to the cells. Six hours 
later, these cells were inoculated with coxsackievirus 83. at a multi- 
plicity of infection of 5 plaque-forming urfits (PFU)/cell. Viral titers 
were determined 24 h after infection. N ‘-Nltro-L-arginine methyl ester 
(bars c and d), but not N”-nitro-o-arginine methyl ester (bars e and f), 
substantially reduced the ability of activated macrophagcs to inhibit 
coxsackievirus 83 replication (bar b). Bar a = control (i.e.. titer of 
coxsackievirus B3 alone). p < 0.01 for har a versus hars b, c and f: bar 
b versus bars c and d: bar c versus bars e and c har d versus bars e and 
f. *p < 0.01 versus bar h (see text for details). 
In Viva Study 
Experiment I: effects of nitric oxide inhibition on acute 
viremic stage. Survival rate. Three mice in the control group, 
5 in the N”-nitro-o-arginine methyl ester group and 14 in the 
NG-nitru-L-arginine methyl ester group had died by day 14. 
corresponding to survival rates on day 14 of 87.0% (20 of 23). 
78.6% (22 of 28) and 58.8% (20 of 34), respectively. The 
difference between the control group and the NG-nitro+- 
arginine’ methyl ester-treated group was significant (p < 0.05 
by the Kaplan-Meier method). 
Myocardial vims titers. Myocardial virus titers on day 4 
(4.4 ? 3.5 X lo3 plaque-forming unitslmg tissue, n = 6) and 
day 7 (1.0 2 0.9 x lo’, n = 13) were significantly higher (p < 
0.05) in the NG-nitro-L-arginine methyl ester group, but not in 
the NG-nitro-D-arginine methyl ester group (day 4: 2.2 2 1.2 X 
lo”, n = 6, day 7: 4.5 2 3.8 X ld, n = 13), than in the control 
group (day 4: 9.0 ? 4.8 X ld, n = 6; day 7: 3.3 + 3.4 X ld, 
n = 13). No virus was isolated from the hearts on day 14 in 
either group (each n = 4). 
Pathologic anulysis (Tub/e I). Cellular’ infiltration was more 
severe on days 4, 7 and 14 in the NG-nitro-L-arginine methyl 
ester group than in the control group. Myocardial riecrosis and 
calcification on days 7 and 14, but not on day 4, were more 
severe in the @-nitro-L-arginine methyl ester group than in 
the control group. Myocardial fibrosis on day 14. but not,on 
day 7, was more severe in the NG-nitro-L-arginine methyl ester 
group than in the control group. Myocardial fibrosis on day 4 
JACC VIII. 2X. No. 6 
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Table 1. Caldiac Pathology in Experiments 1 and II 
Control L-SrWE WNAME 




Infiltration U.Y 5 11.: 1,s -t u.1- 1.3 2 IL.5 
N~rot;i~ II. z Oh ’ ’ 1 Ihi ..- - II.8 5 II.6 
CdlLihMion IL.5 f II.5 1 1 ” 1l.h .- 0.7 z 0.s 
(11 = 6) (n = 6) (n = 6) 
Day 7 
IIltilti‘lllon 1.6 _t 0.7 3.7 2 U.Y * 3.3 -c 0.Y 
ELcrosis 2.1 ? U.8 3.1 z u.Lr* 2.7 2 0.8 
Calcilication 2.13 + 0.4 2.9 f ah* 2.5 2 0.6 
Fibwsis 0.3 + 0.3 (1.5 f 0.4 0.4 2 0.3 
(n = 13) (II = 13; (n = 13) 
Day 1-I 
Inlil~ralion 2.7 ? 0.x 3.5 + 1.1’ 3.0 z 0.7 
Nrcrosis 2.3 + 0.6 3.1 2 U.8 2.8 + u.n 
Calcification 2.1 k 0.7 2.8 2 (1.6’ 2.3 % 0.7 
Fibrosis 1.5 z 0.6 2.3 2 ma* I.8 2 0.6 
(n = 13) (n = 34) (n = 28) 
Experiment II 
Day 35 
Infiltration 0.6 + 0.5 2.0 z 0.7t 1.1 2 U.6 
Necrosis 0.4 2 0.7 1.8 + 0.H 1.0 k 0.6 
Calcitication 0.5 z Il.6 1.6 2 O.St 1.0 ? 0.7 
Fibrosis U.6 k 0.6 I.9 * u.st I.1 -e 0.6 
(n = 16) (n = Ih)+ (n = 16) 
‘p < 0.05. tp < 0.01 versus control. *Hearts of two mice that died on days 
16 and I7 were included. Data presented arc mean value 2 SD. o-NAME = 
N”-nitro-o-argininr methyl ester: L-NAME = N”-nitrw-arginine methyl ester. 
was not e\&ated. Multifocal lesions of thin perivascular 
fibrosis adjacent to necrotic myocytes were noted in all three 
groups. However, there were no significant pathologic abnor- 
malities in the coronary vasculature among the three groups. 
ti-nitro-o-arginine methyl ester administration was ineffec- 
tive. 
Uninfected groups. No mice died by day 14 in any of the 
groups. Pathologic examination revealed no abnormalities in 
the myocardium in any group. 
Experiment II: effects of nitric oxide inhibition on chronic 
aviremic stage. Survival mte. Only two mice (2 [12.5’S] of 16) 
in the NG-nitro-L-arginine methyl ester group had died by day 
35. No mice in the NG-nitro-o-arginine methyl ester or the 
control group had died. Thus, the survival rates were not 
different among the three groups. 
Pathologic analysis (Fig. 2, Table 1). Infiltration. necrosis, 
calcification and interstitial fibrosis were more severe in the 
I@-nitro+-arginine methyl ester group, but not in the I@- 
nitro-o-arginine methyl ester group, than in the control group. 
1~ the NG-nitro-L-arginine methyl ester group, perivascular 
fibrosis was more dense, and &dial swelling was thicker, 
especially in the arteries adjacent to necrotic areas, than in the 
other two groups. Accordingly, vascular &ctural remodeling 
in myocarditis by p-nitro-r-arginine methyl ester treatment 
was considered significant. 
JACC Vol. 2X. No. 6 
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Figure 2. Histopathologic studies. 
In mice killed on day 35 (experi- 
ment II), severe cardiomyopathic 
lesions (i.e., dilated ventricles with 
remodeling, myocardial necrosis. 
cakitkation and interstitial fibrw 
sis, were seen in the No-&o+- 
arginine methyl ester-treated group 
(B, D, F). These lesiins were not 
marked in the infected untreated 
group (A, C, E). Perivascular fibre 
sis and medial thickening were more 
severe in NG-IlitKn-m metbyi 
ester-treated (II, J) than the in- 
fected untreated group (C, I). A 
and B: hematoxylin-eosin, ~15, 
reduced by 60% and 55%, respec- 
tively. C and D, Hematoxylin- 
eosin, X100, reduced by 52%. E 
and F, Mallory-Azan, ~100, re- 
duced by 52%. C and II, MaUory- 
Azan. Xl,ooO, reduced by 52%. I 
and J, Elastic van Gieson, X l,ooO, 
reduced by 52%. A and B: scale = 
0.1 mm. 
\ 
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Discussiop 
Cbxsackievirus B3, myocarditik and ni!ric‘ oxide. The 
‘present study clearly demonstrated that N”-nitro-I.-arginine 
‘methy! ester, a nitric oxide synthase inhibitor, increased myo- 
cardial virus titers. resulting in the aggravation of myocardial 
lesions in the early stage of coxsackievirus 83 myocarditis and 
induced more severe cardiomyopathic lesions in the later 
stage. In contrast, N”-nitro+-arginine methyl ester, the inac- 
:tive enantiomer. was ineffective. On stimulation with INF- 
gamma and lipopolysaccharide, macrophages decreased cox- 
sackievirus B3 titers. Restored coxsackievirus B3 titers in 
INF-gamma- and lipopolysaccharide-stimulated macrophages 
by treatment with NG-nitro-L-arginine methyl ester, but not 
with N”-nitro-o-arginine methyl ester, were observed in the in 
vitro study. Thus, nitric oxide played a protective role in the 
development of acute and chronic coxsackievirus 83 myocar- 
ditis. 
Antiviral effects of nitric oxide. The transformed murine 
macrophage cell line RAW264.7 is highly nonpermissive for 
coxsackievirus B3 replication in the inactivated state. The virus 
yields were almost 10J-fold less than those of VERO cells in 
the present study (data not shown). Treatment with N”-nitro- 
L-arginine methyl ester, but not NG-nitro-D-arginine methyl 
ester, reduced the ability of activated macrophages to suppress 
coxsackievirus B3 replication. 
Nitric oxide in acute myacarditis. In the first in vivo 
experiment, a relation between myocardial virus titers and 
pathologic abnormalities was observed in the acute viremic 
experimental protocol, suggesting that nitric oxide plays a 
defensive role in the early stage of infection. Cal,diac patho- 
lngic scores on days 4. 7 and 14 were higher, and myocardial 
virus titers on days 4 and 7 were higher, in the N”-nitro+- 
arginine methyl ester group than in the control group. In a 
previous in vitro study, Lowznstein et al. (i9) reported that 
nitric oxide played a role in limiting coxsackievirus B3 replica- 
tion when nitroprusside, a donor of nitric oxide, was added to 
HeLa cells. Nitric oxide may be cytostatic or cytotoxic for 
invading microorganisms. An antiviral effect of nitric oxide has 
been demonstrated (15) against herpes simplex virus type 1. 
Nitric o4de in chronic myocarditis. In the second set of in 
vivo exp, !tments, it was clearly demonstrated that nitric oxide 
synthase inhibition aggravated cardiac pathogenesis of chronic 
coxsackievirus B3 myocarditis. Indeed, there is increasing 
evidence that nitric oxide plays an important role in other 
chronic, nonviral inflammatory responses. For example, im- 
mune complex-induced vascular injury in rat lungs and dermal 
vasculature can be attenuated by nitric oxide synthase inhibi- 
tors (20). Furthermore, inhibitors of nitric oxide synthase 
ameliorate experimentally induced chronic. ileitis (21). How- 
ever, there have been reports suggesting that both inhibitors of 
nitric oxide synthase and nitric oxide donors protect against 
some forms of injury. This protection is probably due to the 
dual nature of nitric oxide, which is on the one hand cytotoxic, 
and on the other a vasodilative agent and is thus potentially 
protective (14). 
Nitric oxide regulates vasomotor tone (2223) and inhibits 
leukocyte and lymphocyte adherence and chcmotaxis (24-26). 
Accordingly, reduced and diminished nitric oxide production 
may facilitate .platelet aggregation. leukocyte adhesion and 
even smooth muscle proliferation. Although further studies 
are necessary, the enhancement of myocardial lesions by 
treatment with No-nitro-t.-arginine methyl ester seen in the in 
vivo experiment may have been due to impaired regulation of 
vasomotor tone and aggregation of leukocytes or lymphocyte 
adherence and chemotaxis. 
Nitric oxide in myocardlal architectural remodeling. 
Treatment with N”-nitro+-arginine methyl ester (i.e., inhibi- 
tion of nitric oxide synthesis) not only increased interstitial and 
pcrivascular fibrosis. but also induced more severe architec- 
tural vascular remodeling at the cardiomyopathic stage of this 
study. A mechanism by which nitric oxide may inhibit mito- 
genesis and proliferation of interstitial connective tissue as well 
as vascular smooth muscle has been proposed (27). Recently, it 
was demonstrated (25) that L-arginine treatment reduced 
myocardial fibrosis in another murine model of cardiomyopa- 
thy. Accordingly, we considered treatment with N”-nitro-t.- 
arginine methyl ester to be closely related to myocarditic and 
postmyocarditic ventricular and vascular remodeling in view of 
the observed effects on interstitial and perivascular fibrosis. 
Implications and limitations of the present study. Al- 
though the key findings of this study showed small changes in 
viral titers, survival rates and pathologic grades, we consider 
that these were due to the oral administration protocol of the 
drugs. We did not directly measure nitric oxide production, 
,and therefore no evidence of alteration in nitric oxide metab- 
olism was obtained. Indeed, the inactive NG-nitro-D-arginine 
methyl ester group demonstrated an intermediate effect be- 
tween the NG-nitro+-arginine methyl ester and the control 
groups. We were unable ‘to determine why there were no 
statistically significant differences in any of the variables of 
pathologic grades between the NG-nitro-L-arginine methyl 
ester and NG-nitro-D-arginine methyl ester groups. There is a 
common mechanism of action by both enantiomers on the 
effect of viral myocarditis (i3,14), which may be due to 
mechanisms other than interference of nitric oxide synthase. 
Accordingly, the observed effects may have been due in part to 
nonspecific interactions of the drugs with nitric oxide synthase. 
Further studies will be needed to clarify these issues. 
Conclusions. Treatment with the nitric oxide inhibitor 
NG-nitro-L-arginine methyl ester aggravates both acute cox- 
sackievirus B3 myocarditis by increased myocardial virus rep- 
lication and chronic coxsackievirus B3 myocarditis by inducing 
more severe cardiomyopathic lesions. In vitro analysis of nitric 
oxide inhibition by, treatment of the murine macrophage cell 
line RAW264.7 with NG-nitro-L-arginine methyl ester. may 
explain the possible in vivo anti-coxsackievirus 83 activity of 
nitric oxide in this experimental model. Thus, we demonstrated 
experimentally that nitric oxide plays a defensive role in the 
pathogenesis of coxsackievirus B3 myocarditis. 
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